Post Type Description
William Tai is a successful entrepreneur and investor with over 30 years of experience in the technology industry. He is the Founder and Managing Partner of Amed Ventures, a San Francisco Bay Area-based venture capital fund focused on Medical Device and Medical Technologies investments.
He is also the former VP of Business Development at CTBC Bank Corp. William has earned a Bachelor’s Degree in Finance from National Chengchi University and an MBA from Baruch College.
Stavros G. Vizirgianakis was the former Chief Executive Officer of Misonix (MSON) from 2016- 2021. He has a distinguished career in the medical devices field having worked for United States Surgical Corporation as director of sales for sub-Saharan Africa and later Tyco Healthcare in the capacity of General Manager South Africa.
In 2006, Vizirgianakis co-founded Surgical Innovations, one of the largest privately owned medical device distributors in the African region which later became part of the Ascendis Health group. He also served on the boards of Tenaxis Medical and Bioventus. Current board positions include Tally Surgical and Theragenics.
He is a strategic investor and advisor to numerous startups and established companies in the medical device field. Vizirgianakis has a Degree in Commerce from the University of South Africa.
Calvin Portley has extensive work experience in various roles and industries with much of his time spent in healthcare technology commercialization. Calvin is the Chief Business Officer at Neurolutions, a position he has held since May 2020. Prior to that, he worked as a Venture Partner at Dangerous Ventures and the Managing Partner at Avon Growth Management, a lower middle market acquisition firm. Before that, he worked in various marketing and sales leadership positions at Doctor On Demand, Beckman Coulter, Johnson & Johnson, Alcon (a Novartis company), and The Kraft Heinz Company.
Calvin Portley completed his Master of Business Administration (M.B.A.) degree from the UCLA Anderson School of Management in 2014 and obtained his Bachelor of Business Administration (B.B.A) in Marketing from The University of Texas at Arlington in 2003.
Sean has extensive professional experience ranging from acute clinical practice to healthcare entrepreneurship. Data analysis and commercial viability drive his work, helping demystify intricacies to enhance both healthcare delivery and business operations. His personal mission is to revolutionize healthcare by integrating cutting-edge technology with human-centric care, ensuring accessibility, efficiency, and excellence. His journey has been characterized by a relentless pursuit of innovation and efficiency. He seeks opportunities to serve as an innovation catalyst, working with forward-thinking organizations and individuals to develop solutions that truly make a difference. Through perseverance, creativity, and a priority-driven focus on value, he aspires to lead the next wave of breakthroughs that fundamentally reshape how health is defined, delivered, and experienced.
Nancey Trevanian Tsai, MD is a board certified Sports Medicine Physician, Diplomate of the American Board of Physical Medicine and Rehabilitation. She is a Clinical Professor of Neurosurgery at the Medical University of South Carolina. She is also the Clinician representative for the IEEE Engineering in Medicine and Biology AdCom, an officer of the South Carolina section of the IEEE, as well as a past Chair of the American Council on Exercise, a past Chair of the South Carolina Medical Association Young Physicians Section, a member of the Medical Society of South Carolina. She has a patent for the Blink Reflexometer in Australia and Japan, and the United States. She has also been a member of the USA Field Archery Team in 2010, 2012, and a national coach for USA Archery/Para- archery, whose athletes include national and world champions.
Kirsten joined Imperative Care in October 2017 as Vice President Strategic Development, and in early 2020 founded the company’s Patient-at-Home initiative, the development program that served as the basis for the creation of Kandu. Previously, she spent a combined nearly 15 years in the Neurovascular Division of Stryker and Boston Scientific, where she held strategic development, planning, marketing, and product management positions. Kirsten holds several patents in the fields of stroke treatment and detection, and she is the author of several peer-reviewed papers in the field of stroke and access to care.
Internationally acclaimed neurologist and researcher, Tudor G. Jovin, MD, is based at Cooper University Hospital in Camden, New Jersey and presides as the Chief and Chairman of Cooper Neurological Institute. Dr. Jovin is an expert in the interventional and non-interventional treatment for the entire spectrum of stroke and cerebrovascular disorders. He was one of the nation’s first interventional neurologists, a medical subspecialty that uses minimally invasive technologies applied from within the vessels to diagnose and treat diseases of the arteries and veins of the head, neck, and spine such as acute stroke, carotid stenosis, intracranial aneurysm, and arteriovenous malformations. In addition to his clinical experience, Dr. Jovin is known internationally for his research activities. He has served as principal investigator for several international clinical studies including REVASCAT, a randomized trial of endovascular therapy versus medical therapy for acute stroke within eight hours of symptoms onset conducted in Spain, and DAWN, a multicenter, international, randomized trial of endovascular therapy versus medical therapy in the beyond eight-hour time window. Both studies are considered landmark studies in the development of treatments for acute stroke and have been published in the New England Journal of Medicine. He is a member of the executive or steering committees for several multicenter national and international trials, and has participated as site principal investigator or co-investigator in multiple national and international trials. Additionally, he serves as editorial board member for numerous medical journals. Dr. Jovin has published more than 300 articles in peer-reviewed journals or book chapters. The consequential nature of his research is evidenced by recently published studies that have identified Dr. Jovin as the highest impact author in the neuro-interventional field. Prior to joining Cooper, Dr. Jovin was a professor of neurology and neurosurgery at the University of Pittsburgh School of Medicine and director of the Center for Neuroendovascular Therapy at the University of Pittsburgh Medical Center (UPMC). At UPMC, he also served as the director of UPMC’s Stroke Institute, one of the leading centers for stroke care, education, and research in the world.
